5.06
-0.08 (-1.56%)
| Penutupan Terdahulu | 5.14 |
| Buka | 5.11 |
| Jumlah Dagangan | 348,846 |
| Purata Dagangan (3B) | 1,129,218 |
| Modal Pasaran | 274,208,288 |
| Harga / Pendapatan (P/E TTM) | 4.18 |
| Harga / Pendapatan (P/E Ke hadapan) | 526.32 |
| Harga / Jualan (P/S) | 745.81 |
| Harga / Buku (P/B) | 1.48 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 17 Mar 2026 |
| EPS Cair (TTM) | -0.630 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 57.92% |
| Nisbah Semasa (MRQ) | 4.90 |
| Aliran Tunai Operasi (OCF TTM) | -59.88 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -39.71 M |
| Pulangan Atas Aset (ROA TTM) | -49.95% |
| Pulangan Atas Ekuiti (ROE TTM) | -271.78% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Abeona Therapeutics Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.5 |
| Purata | -0.25 |
|
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company’s development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 5.84% |
| % Dimiliki oleh Institusi | 63.35% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Nan Fung Trinity (Hk) Ltd | 31 Dec 2025 | 956,770 |
| Julat 52 Minggu | ||
| Median | 20.00 (295.26%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 10 Mar 2026 | 20.00 (295.26%) | Beli | 5.14 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 31 Dec 2025 | Pengumuman | Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |